Drug Profile

Brilacidin coronavirus vaccine - Innovation Pharmaceuticals

Alternative Names: COVID-19 vaccine - Innovation Pharmaceuticals

Latest Information Update: 26 May 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Innovation Pharmaceuticals
Developer Innovation Pharmaceuticals; University of Pennsylvania
Class COVID-19 vaccines
Mechanism of Action Immunostimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 May 2020 Discontinued - Preclinical for COVID-2019 infections (Prevention) in USA (IV)
06 Apr 2020 Innovation Pharmaceuticals plans a clinical trial for COVID-2019 infections in the US and Europe
17 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com